CC
ADVM

CQS Cayman’s Adverum Biotechnologies ADVM Stock Holding History

CQS Cayman’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-13,841
Closed -$1.14M – 140
2015
Q3 		$1.14M Buy
+13,841
New +$1.77M 0.09% 110
2015
Q1 		– Sell
-6,600
Closed -$3.56M – 209
2014
Q4 		$3.56M Buy
6,600
+3,300
+100% +$1.27M 0.24% 86
2014
Q3 		$1.13M Buy
+3,300
New +$982K 0.07% 122

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

CQS Cayman's ADVM Position: Q4 2015 in Review

CQS Cayman sold out of Adverum Biotechnologies (ADVM) in Q4 2015, closing a stake of 13,841 shares — an estimated $1.14M sold.

CQS Cayman first reported a position in ADVM in Q3 2014 and held it in 3 quarters. The position peaked at $3.56M in Q4 2014. 76 funds tracked by Wall St. Rank hold ADVM as of Q4 2015.

  • CQS Cayman reported no remaining Adverum Biotechnologies position as of Q4 2015 after selling out during the quarter.
  • CQS Cayman sold 13,841 Adverum Biotechnologies shares in Q4 2015, an estimated $1.14M.
  • CQS Cayman first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 3 quarters.
  • CQS Cayman's Adverum Biotechnologies position peaked at $3.56M in Q4 2014.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2015.

Based on CQS Cayman's 13F filing for Q4 2015, filed 11 Feb 2016.